176: Reduced intensity conditioning (RIC) and hematopoietic stem cell transplantatiation (HSCT) using photopheresis (ECP), fludarabine, and targeted single dose busulfan as an outpatient procedure in children Preliminary results by Schneiderman, J. et al.
Allogeneic hematopoietic stem cell transplantation is the only
curative therapy. Many patients do not have a suitable donor.
Between 1995 – 2006, 25 pediatric patients lacking matched
living stem cell donors were transplanted with unrelated umbil-
ical cord blood (UCB). M:F ratio of the study group was 1.8;
Eight (32%) patients belonged to ethnic minorities; the median
age was 9.77 years (range 1.11-19.73) and median weight was
32.8 kg (range 8.3-62.6). Five patients had therapy-related MDS
(3 ALL, 1 NHL, 1 Neuroblastoma). MDS stage was RA/RC 10
pts, RAEB 7 pts, RAEB-T 3pts, and AML 5 pts. Monosomy 7
was present in 17 (68%) pts. Median time from diagnosis to
transplant was 7.17 months (range 2-61). Preparative regimen
was TBI based in 17 pts (68%). Cyclosporine was used for
GVHD prophylaxis with Solu-medrol in 24 pts and CellCept in
1 pt. Grafts were matched at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level. 6 pts
were 5/6, 18 pts were 4/6, and 1 pt was 3/6 HLA matched. The
grafts contained a median of 4.39  10e7 (range 1.68-29.16)
nucleated cells/kg pre-cryopreservation and 3.58  10e7/kg
(range 1.01-21.25) infused. The median CD 34 cell dose
infused was 1.5  10e5/kg (range 0.17-28.46). Cumulative in-
cidence of neutrophil engraftment (ANC  500/ L) at day 100,
platelet engraftment (50K untransfused) at day 180, acute
GVHD grades 2-4 at day 100, chronic GVHD, relapse and non
relapse mortality at 1 yr were 72%, 56%, 20%, 32%, 8% and
36.5% respectively. 5 yr probabilities of OS and EFS were 46%
and 41%. Thirteen patients died, 5 of infectious complications
(1 toxoplasmosis, 1 aspergillosis, 2 EBV including 1 LPD, 1
adenovirus), 4 of relapse, 1 of graft failure, and 3 of multi system
organ failure. EFS of pts  10 yrs of age (p  0.05) , weighing
 33kg (p  0.03), and those with monosomy 7 (p  0.05) was
superior. These results, especially in younger patients with
Monosomy 7 and early stage MDS are equivalent to matched
allogeneic bone marrow transplant data. We conclude that un-
related UCB donors should be actively considered for pediatric
patients with MDS who lack a living related or unrelated stem
cell donor to enable transplantation when the disease is in early
stage.
Event Free Survival by Covariates
N Events
1 yr estimate
%(95% CI)
3 yr estimate
(95% CI) p-value
KARYOTYPE 0.05
Monosomy 7
present
17 8 64.7 (42-87.4) 58.8 (35.4-82.2)
Monosomy 7
absent
8 6 37.5 (4-71) 18.8 (0-49.7)
RECIPIENT AGE 0.05
> 10 years 11 9 45.5 (16-74.9) 27.3 (1.0-53.6)
< 10 years 14 5 64.3 (39.2-89.4) 64.3 (39.2-89.4)
RECIPIENT WT. 0.03
> 33 kg 12 10 41.7 (13.8-69.6) 25 (0.5-49.5)
< 33 kg 13 4 69.2 (44.1-94.3) 69.2 (44.1-94.3)
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MYELOABLATIVE HSCT FOR CHILDREN AND ADOLESCENTS WITH LYM-
PHOMA REFRACTORY TO PRIMARY THERAPY: A SINGLE INSTITUTION
EXPERIENCE
Quinones, R.1, Peltz, A.1, Malcolm, J.1, Hild, E.1, Gore, L.1,
Foreman, N.1, Christensen, M.1, Croskell, M.1, Kissane, R.1, Giller, R.1
1University of Colorado and The Children’s Hospital, Denver, CO.
Primary therapy of high-risk lymphomas in children and ad-
olescents is very successful, however refractory lymphoma pre-
sents major challenges and optimal therapy remains uncertain.
Between 1994 and 2006, 22 pediatric patients with high-risk
lymphoma underwent myeloablative therapy and HSCT; 16
autologous and 7 allogeneic (5 sibling; 2 unrelated HSCT). The
overall EFS was 61% with a median follow up in survivors of
1243 days after HSCT. In 8 Hodgkin’s patients the overall EFS
was 54%; all patients had failed primary therapy, received au-
tologous PBPC and engrafted and one had a planned non-
myeloablative sibling allogeneic HSCT. Relapse occurred in 3
of 4 patients not in CR at 181, 248 and 812 days from HSCT.
In contrast, the 4 of the 5 relapse-free survivors (median follow
up of 833 days; range 305 to 2127) had attained a CR2. The 14
NHL patients’ diagnoses included 6 anaplastic large cell lym-
phomas, 2 peripheral T lymphomas and 6 lymphoblastic lym-
phomas (4 T and 2 B precursor phenotype). Allogeneic HSCT
were performed in 7 NHL patients (5 MS; 2 URD), while 8
patients received autologous PBPC (one autologous patient
relapsed at day 60, then received an allograft). All relapses
occurred before day 100 and 4/5 relapses were in patients who
either had CNS relapses and/or had residual disease at the time
of HSCT. The EFS for all NHL patients was 67% with a
median follow up in survivors of 1756 days (range 224 to 3606
days). In autologous HSCT recipients, the EFS was 50% (me-
dian follow up in survivors was 1071 days; range 224 to 2527),
while after allogeneic HSCT for NHL, the EFS was 83%
(median follow up in survivors was 2283 days; range 496 to
3606). There were no toxic deaths in any patient group. GVHD
occurred in 3/7 allogeneic HSCT patients and resolved with
therapy in all patients. Opportunistic infections typical for al-
logeneic HSCT (speciﬁcally aspergillus, CMV and RSV) oc-
curred more often in the lymphoma patients undergoing autol-
ogous PBPC HSCT compared to pediatric autologous HSCT in
patients with solid tumors. We conclude that myeloablative
HSCT offers signiﬁcant salvage potential in patients with lym-
phoma who have disease refractory to primary therapy. Those
patients who attain disease control prior to HSCT do very well.
We prefer to use TBI-based myeloablation and perform alloge-
neic HSCT in pediatric NHL patients to overcome potential
chemotherapy resistance, decrease the potential of re-infused
tumor and to potentially elicit a GVL effect.
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REDUCED INTENSITY CONDITIONING (RIC) AND HEMATOPOIETIC
STEM CELL TRANSPLANTATIATION (HSCT) USING PHOTOPHERESIS
(ECP), FLUDARABINE, AND TARGETED SINGLE DOSE BUSULFAN AS AN
OUTPATIENT PROCEDURE IN CHILDREN: PRELIMINARY RESULTS
Schneiderman, J.1, Duerst, R.1, Tse, W.1, Thormann, K.1, Kletzel, M.1,
Jacobsohn, D.A.1 1Northwestern University, Chicago, IL.
ECP is an immunomodulatory therapy for immune-mediated
disorders, including GVHD. We hypothesize that combining
ECP with RIC prior to and following HSCT will reduce inci-
dence of GVHD and 100-day transplant related mortality
(TRM) without affecting time to engraftment. Ten children
have been enrolled with a mean age of 14 years (10 – 17), with
CML (n2), severe aplastic anemia (SAA) (n4), ALL in CR2
(n1), peripheral T-cell lymphoma (n1), and relapsed
Hodgkin’s after autologous transplant (n2). Stem cell sources
included peripheral blood from matched related (n6), mis-
matched related (n1), and matched unrelated (n3) donors.
Conditioning included 2 weekly treatments of ECP (treat-
ment2 consecutive days) beginning two weeks prior to trans-
plant, ﬂudarabine 30mg/m2/d (days -6 to -2) and targeted dose
busulfan to reach a daily AUC of 4000 mol*min (days -5, -4);
GVHD prophylaxis was: MMF, CSA, and weekly ECP once
total chimerism reached 50% through day 100. Median fol-
low-up is 100 days (33 – 446). Full engraftment (95% total
donor chimerism) was achieved by a median of 29 days (12 – 81)
in 9/10 patients. Two required immune modulation for falling
chimerism; 1 responded to removal of immune suppression, 1
required donor lymphocyte infusion. Major complications were
infectious: central line infections (n5, with 1 episode of hypo-
tension), adenovirus antigenemia (n1), and CMV reactivation
(n5/5 at risk); they underwent pre-emptive treatment without
development of disease. There was 1 TRM: a patient with
heavily treated SAA died of fungal infection after no engraft-
ment. Acute GVHD only occurred in those undergoing immune
modulation (2/10, grade 3). Of 8 evaluable, 2 developed exten-
sive cGVHD; 1 limited. There were no episodes of veno-
occlusive disease or mucositis; none required parenteral nutri-
tion. Patients were admitted to the hospital for 2 days during the
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preparative regimen (IV busulfan); from day 0 to 100 patients
were admitted for a median of 11 days (0 – 25). We conclude
that in children, using ECP as part of RIC and GVHD preven-
tion is well tolerated and feasible, time to engraftment is ac-
ceptable, and complications are minimal as evidenced by short
inpatient stays. However, immune suppression appears to be
excessive given the rates of CMV reactivation and declining
chimerism of two patients while on ECP. ECP appears to be
effective in preventing aGVHD, as the only patients who de-
veloped aGVHD were those requiring immune modulation.
Table #1
Daignosis Donor
Chimerism
> 50%
(days)
Chimerism
> 95%
(days) aGVHD cGVHD
Disease
Status
1 CML Matched
Sibling
13 29 None None NED
following
DLI &
Imatinib
for
rising
BCR/ABL,
day
446
2 SAA Matched
Sibling
8 26 None Extensive NED,
day 390
3 CML Matched
Sibling
26 63
(Following
DLI)*
Grade 3 Extensive NED,
day 340
4 SAA Mismatched
Related
12 81
(Following
removal of
immune
supression)*
Grade 3 Limited NED,
day 284
5 Relapsed
ALL (CR2)
Matched
Sibling
12 28 None None Relapse,
day 100
6 Recurrent
HD (CR3)
MUD 20 33 None None Relapse,
day
100,
died of
PD
7 SAA Matched
Sibling
7 12 None None NED,
day 187
8 Recurrent
HD (CR2)
Matched
Sibling
28 47 None None NED,
day 124
9 SAA MUD No
engraftment
No
engraftment
None N/A Died
day
37,
fungal
infection
10 Peripheral
T-cell
Lymphoma
MUD 12 12 None N/A NED,
day 33
*Interventions due to falling chimerism
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COMBINED TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL
(MMF) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN
CHILDREN UNDERGOING CORD BLOOD TRANSPLANTATION (CBT)
Soni, S.1, Hente, M.2, Breslin, N.2, Bertolone, S.2, Cheerva, A.2 1Co-
lumbus Children’s Hospital, Columbus, OH; 2Kosair Children’s Hospi-
tal, Louisville, KY.
Background: Effectiveness of FK-506 and MMF combination as
prophylaxis for GVHD is still under investigation. We studied the
feasibility and effectiveness of this regimen in preventing GVHD
in children undergoing matched unrelated donor (MUD) CBT to
avoid methotrexate and methylprednisone toxicity.
Patients and Methods: Between 5/1/04-9/1/06, 11 children
undergoing MUD CBT have received FK-506 and MMF combi-
nation as prophylaxis for GVHD. Thymoglobulin (Rabbit ATG,
2.5-5mg/kg total) was used as part of the conditioning regimen.
Both myeloablative (n9) and non-myeloablative (n2) prepara-
tive regimens were used and majority of the children (n7) have
received one antigen mismatch (Class I/II-antigen disparate) CBT.
FK-506, 0.015mg/kg IV every 12 hours (infused over 6 hours) was
started on day-2 (trough level maintained 5-15 ng/ml),rather than
as a continuous infusion. MMF was started on day 1 at 15mg/kg
/dose IV q 8-12 hours and stopped on day 30, if there were no
signs of GVHD. Both were converted to PO formulation at the
time of discharge. MMF levels (active MPA) were monitored
weekly.
Results: The regimen was well tolerated. Only major side-effect
noted was hypertension in the ﬁrst 2 patients, which was controlled
with prophylactic anti-hypertensive use in subsequent patients.
Tremors occurred in 2 patients and responded to MMF taper. No
major neuro- or nephrotoxicity was noted. All children have en-
grafted (median16 days). No patient has developed Grade II
GVHD (Glucksberg staging criteria). 6/11 patients (54.5%) had
developed Grade I/II GVHD, limited only to skin and gut (1 pt.)
that was steroid-responsive. Only 1/6 patients continued to have
limited chronic GVHD of the skin (median follow-up: 255days ;
range: 62-725 days). Immune-reconstitution was not delayed.
MMF levels ranged from 0.5-5.7 mcg/ml. No correlation was
seen between the MMF levels and the incidence of GVHD in this
study.
Conclusion: FK-506/MMF combination is well tolerated, does
not affect engraftment kinetics or immune-reconstitution and is
efﬁcacious in preventing GVHD in CBT.
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HHV-6 INFECTION FOLLOWING CAMPATH1H BASED REDUCED INTEN-
SITY CONDITIONING (RIC) REGIMEN IN PEDIATRIC PATIENTS UNDER-
GOING SCT FOR NON-MALIGNANT DISORDERS
Soni, S.1, Barnes, Y.2, Hayashi, R.2, Manna, P.3, Shenoy, S.2 1Colum-
bus Children’s Hospital, Columbus, OH; 2Wahington University School
of Medicine, St. Louis, MO; 3Dept. of Molecular Diagnostic Research,
Viracor Laboratories, Lee’s Summit, MO.
Background: Human Herpes Virus 6 (HHV-6) infections have
been recently recognized as complications of SCT in young pa-
tients. Limited information is available on patterns and impact of
HHV-6 infection following RIC transplants using increased im-
munosuppression. We describe our multi-institutional experience
with HHV-6 infections during SCT following a Campath IH
based RIC regimen.
Patients and Methods: 12 patients underwent SCT for non-
malignant disorders and received Campath 1H (33mg/48mg, day
-21 and day-19); Fludarabine (150mg/m2,day -8 to -4) and Mel-
phalan (70 or 140mg/m2, day-3) prior to stem cell infusion (BM/
PBSC/CB) from related or unrelated donors. Two patients had
also received Thiotepa (10mg/kg on day-2). Acyclovir was used for
viral prophylaxis. Patients were tested for HHV-6 pre-transplan-
tation by a PCR based assay. Patients were monitored by HHV-6
PCR if they had fever, delayed engraftment/myelo-suppression,
rash or malaise. Serial quantitative real-time PCRs (viral load) data
was collected in some of these patients (Viracor Laboratories,
Missouri) to gauge response to treatment.
Results: All 12 patients undergoing SCT were negative for
HHV-6 by PCR pre-transplant. 7 patients (58.3%) had HHV-6
detected during the course of their SCT. Infections occurred
during the ﬁrst month (n4), second month (n1), at 4 months
(n1) and at 6months (n1) post-SCT. Common symptoms en-
countered were fever, rash and pancytopenia/delayed engraftment.
No case of pneumonitis or encephalitis was seen. HHV-6 infection
responded rapidly to Foscarnet or Gangcyclovir with decrease in
viral load and was associated with no deaths. No HHV-6 infections
were seen after immune-reconstitution (6 months).
Conclusions: Infection with HHV-6 infection is more frequent
following Campath based regimen. Most of the infections occur
within the ﬁrst 4 weeks and may delay engraftment; but late
infections are also common due to intense immunosuppression.
Therefore, close monitoring and early treatment is advocated in
pediatric patients receiving Campath 1H.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOLLOW-
ING INTRAUTERINE TRANSFUSIONS FOR TREATMENT OF ALPHA
THALASSEMIA MAJOR
Rivers, A.E.1, Richard, D.1, Harris, N.1, Chui, D.H.K.2,
Slayton, W.B.1, Staba, S.L.1 1University of Florida, Gainesville, FL;
2Hemoglobin Diagnostic Reference Laboratory, Boston, MA.
Homozygous 0-thalassemia (deletion of all 4 -globin genes)
results in Hb Bart’s (4 tetramers). Almost universally fetal death
from hydrops occurs prior to diagnosis, therefore not allowing the
opportunity for treatment. Advancement of maternal-fetal medi-
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